Dark Forest Capital Management LP Sells 686 Shares of Catalent, Inc. (NYSE:CTLT)

Dark Forest Capital Management LP cut its stake in shares of Catalent, Inc. (NYSE:CTLT) by 10.8% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 5,654 shares of the company’s stock after selling 686 shares during the quarter. Dark Forest Capital Management LP’s holdings in Catalent were worth $318,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also added to or reduced their stakes in the company. Corient Private Wealth LLC increased its holdings in Catalent by 14.5% in the 4th quarter. Corient Private Wealth LLC now owns 23,972 shares of the company’s stock worth $1,077,000 after purchasing an additional 3,039 shares in the last quarter. Hsbc Holdings PLC raised its holdings in Catalent by 89.4% in the 4th quarter. Hsbc Holdings PLC now owns 366,224 shares of the company’s stock valued at $16,453,000 after buying an additional 172,902 shares during the last quarter. Parallel Advisors LLC boosted its position in Catalent by 17.4% during the 4th quarter. Parallel Advisors LLC now owns 5,056 shares of the company’s stock worth $227,000 after buying an additional 748 shares during the period. Treasurer of the State of North Carolina grew its holdings in Catalent by 1.0% during the 4th quarter. Treasurer of the State of North Carolina now owns 82,514 shares of the company’s stock worth $3,707,000 after acquiring an additional 785 shares during the last quarter. Finally, Bank of Nova Scotia increased its position in Catalent by 3,203.9% in the 4th quarter. Bank of Nova Scotia now owns 230,874 shares of the company’s stock valued at $10,373,000 after acquiring an additional 223,886 shares during the period.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on CTLT shares. Barclays boosted their price objective on shares of Catalent from $47.00 to $63.00 and gave the stock an “equal weight” rating in a research note on Friday, June 28th. William Blair reissued a “market perform” rating on shares of Catalent in a research note on Tuesday, September 3rd. Royal Bank of Canada restated a “sector perform” rating and set a $63.50 price objective on shares of Catalent in a research report on Thursday, July 11th. Robert W. Baird reissued a “neutral” rating and set a $63.50 target price on shares of Catalent in a research report on Tuesday, September 24th. Finally, StockNews.com assumed coverage on shares of Catalent in a report on Thursday. They set a “sell” rating for the company. One equities research analyst has rated the stock with a sell rating and eight have assigned a hold rating to the stock. According to data from MarketBeat, the stock has an average rating of “Hold” and an average price target of $59.83.

Catalent Price Performance

Shares of CTLT opened at $60.33 on Friday. The firm has a market cap of $10.92 billion, a PE ratio of -9.89, a price-to-earnings-growth ratio of 2.32 and a beta of 1.15. Catalent, Inc. has a 52-week low of $31.80 and a 52-week high of $61.20. The business’s 50 day moving average price is $59.69 and its two-hundred day moving average price is $57.33. The company has a debt-to-equity ratio of 1.35, a quick ratio of 1.96 and a current ratio of 2.52.

Catalent (NYSE:CTLT) last released its earnings results on Thursday, August 29th. The company reported $0.57 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.44 by $0.13. The company had revenue of $1.30 billion for the quarter, compared to the consensus estimate of $1.23 billion. Catalent had a negative net margin of 22.72% and a negative return on equity of 0.56%. On average, equities analysts anticipate that Catalent, Inc. will post 0.85 EPS for the current year.

Insider Activity

In related news, CFO Matti Masanovich sold 2,993 shares of the company’s stock in a transaction that occurred on Monday, July 8th. The stock was sold at an average price of $56.74, for a total transaction of $169,822.82. Following the transaction, the chief financial officer now directly owns 33,871 shares of the company’s stock, valued at approximately $1,921,840.54. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In related news, CFO Matti Masanovich sold 2,993 shares of Catalent stock in a transaction on Monday, July 8th. The shares were sold at an average price of $56.74, for a total value of $169,822.82. Following the completion of the sale, the chief financial officer now owns 33,871 shares of the company’s stock, valued at approximately $1,921,840.54. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Also, CEO Alessandro Maselli sold 9,088 shares of the company’s stock in a transaction on Monday, July 29th. The stock was sold at an average price of $58.76, for a total transaction of $534,010.88. Following the transaction, the chief executive officer now owns 177,521 shares in the company, valued at approximately $10,431,133.96. The disclosure for this sale can be found here. Insiders sold a total of 15,403 shares of company stock worth $902,503 in the last three months. Company insiders own 0.31% of the company’s stock.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.